Our findings suggest that CTGF could participate in Ang II-mediated profibrotic effects in chronic liver diseases and might open up a new strategy to prevent pathological CTGF production in hepatic fibrosis. The gene discussed is CCN2; the disease is Hepatic fibrosis.